BioRestorative Suspends All ExoCR and BioX Orders and Shipments Amid Regulatory Review
BRTX sits 42% above its 52-week low of $0.159.
Summary
BioRestorative Therapies has halted all orders and shipments of its ExoCR and BioX biocosmeceutical product lines effective August 7, pending a review of documentation, sourcing, and regulatory status. The company has not decided to discontinue the products, but the suspension is immediate and total. This follows a turbulent period: CEO and CFO resigned in July claiming a change in control, and the company has a going concern warning and Nasdaq delisting risk. The suspension cuts off a revenue stream and raises questions about regulatory compliance. Watch for the outcome of the review and any further disclosures.
At the time of this announcement, BRTX was trading at $0.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8M. The 52-week trading range was $0.16 to $1.89. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.